Skip to content
Tyra Biosciences logo — TYRA is focused on developing next-generation precision medi...

Tyra Biosciences

TYRA is focused on developing next-generation precision medicines that target large opportunities in FGFR biology.

Founded 2018 United States Carlsbad, United States 85 employees Total: $555.00M Biotechnology, Health and Wellness +1

General Information

Company Name Tyra Biosciences
Founded Year 2018
Location United States Carlsbad, United States
Founders / Decision Makers
Team member Team member
Employees 85
Industries Biotechnology, Health and Wellness, Life Sciences
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Tyra Biosciences. To contact Tyra Biosciences, visit tyra.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Tyra Biosciences compare?

A PDF of Tyra Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Tyra Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Tyra Biosciences

Tyra Biosciences, founded in 2018, is a clinical-stage biotechnology firm headquartered in the United States. The company is developing next-generation precision medicines focusing on large opportunities in FGFR biology. Through its proprietary platform, SNÅP, Tyra Biosciences rapidly refines structural drug design using molecular insights to anticipate genetic alterations that could lead to resistance against existing therapies.

Tyra Biosciences leverages its accelerated small molecule drug discovery engine, targeting niches within oncology and genetically defined conditions, positioning itself within the Biotechnology, Health and Wellness, and Life Sciences industries.

The company recently secured a substantial $200.00M Post-IPO Equity investment in February 2024. Leading investors like RA Capital Management, 5AM Ventures, OrbiMed, Boxer Capital, BVF Partners, and Nextech Invest underscore significant confidence in Tyra's potential for innovation and impactful breakthroughs in precision medicine.

Business keywords: Precision Medicine, FGFR Biology, Oncology, Clinical-stage Biotechnology, SNÅP Platform, Drug Resistance, Fibroblast Growth Factor Receptor (FGFR), Small Molecule Drug Discovery, Bladder Cancer, Genetically Defined Conditions, Targeted Oncology, Structural Drug Design, Selective Inhibitors, Drug Discovery Engine, Tumor Resistance

Services & Products

Development of precision molecules
Clinical research and studies
Oral drug development

Target Customers

Patients with non-muscle invasive bladder cancer (NMIBC) Patients with upper tract urothelial carcinoma (UTUC) Patients with achondroplasia Healthcare professionals Parents or caregivers of children with achondroplasia Advocacy groups related to achondroplasia

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement VC $200.00M 6
RA Capital Management, 5AM Ventures +4
01 Feb 2024
IPO $199.00M -
01 Sep 2021
Series B $106.00M 10
RA Capital Management, Alta Partners +8
01 Mar 2021
Series A $50.00M 5
RA Capital Management, Alta Partners +3
01 Jan 2020

Tyra Biosciences Alternatives & Competitors

View All Alternatives
Tyra Biosciences vs
Flare Therapeutics
Flare Therapeutics United States

Trailblazing the path to drugging transcription factors to discover precision medicines for cancer &...

Series B
62 employees
Biopharma, Biotechnology
Tyra Biosciences vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
182 employees
Biotechnology, Health Care
Tyra Biosciences vs

Overcoming Resistance In Cancer

Post-IPO Equity
119 employees
Biopharma, Biotechnology

FAQ About Tyra Biosciences

TYRA is focused on developing next-generation precision medicines that target large opportunities in FGFR biology.
Tyra Biosciences was founded in 2018.
Tyra Biosciences is headquartered in Carlsbad, United States.
Tyra Biosciences operates in Biotechnology, Health and Wellness and Life Sciences. Its work centres on Precision Medicine, FGFR Biology, Oncology and Clinical-stage Biotechnology. Its customers include Patients with non-muscle invasive bladder cancer (NMIBC), Patients with upper tract urothelial carcinoma (UTUC) and Patients with achondroplasia.
Tyra Biosciences has a B2B business model. Its revenue comes from Licensing and Product Sales.
Tyra Biosciences has approximately 85 employees.
Tyra Biosciences has completed 4 funding rounds, raising a total of $555.00M.
Tyra Biosciences offers: Development of precision molecules, Clinical research and studies, Oral drug development.
Top alternatives and competitors to Tyra Biosciences include Flare Therapeutics, Tango Therapeutics, ORIC Pharmaceuticals Inc., Prelude Therapeutics, Kinnate Biopharma Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tyra Biosciences and Flare Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Tyra Biosciences, https://bouncewatch.com/company/tyra-biosciences, updated 3 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout